MVMDF
Price
$0.01
Change
-$0.01 (-50.00%)
Updated
Aug 15 closing price
Capitalization
5.12M
OASMY
Price
$0.02
Change
-$0.00 (-0.00%)
Updated
Jun 11 closing price
Capitalization
13.67M
87 days until earnings call
Interact to see
Advertisement

MVMDF vs OASMY

Header iconMVMDF vs OASMY Comparison
Open Charts MVMDF vs OASMYBanner chart's image
Mountain Valley MD Holdings
Price$0.01
Change-$0.01 (-50.00%)
Volume$14K
Capitalization5.12M
VIVESTO AB
Price$0.02
Change-$0.00 (-0.00%)
Volume$900
Capitalization13.67M
MVMDF vs OASMY Comparison Chart in %
Loading...
MVMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MVMDF vs. OASMY commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MVMDF is a Hold and OASMY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (MVMDF: $0.01 vs. OASMY: $0.02)
Brand notoriety: MVMDF and OASMY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: MVMDF: 27% vs. OASMY: 100%
Market capitalization -- MVMDF: $5.12M vs. OASMY: $13.67M
MVMDF [@Pharmaceuticals: Generic] is valued at $5.12M. OASMY’s [@Pharmaceuticals: Generic] market capitalization is $13.67M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MVMDF’s FA Score shows that 0 FA rating(s) are green whileOASMY’s FA Score has 0 green FA rating(s).

  • MVMDF’s FA Score: 0 green, 5 red.
  • OASMY’s FA Score: 0 green, 5 red.
According to our system of comparison, OASMY is a better buy in the long-term than MVMDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MVMDF’s TA Score shows that 2 TA indicator(s) are bullish.

  • MVMDF’s TA Score: 2 bullish, 4 bearish.

Price Growth

MVMDF (@Pharmaceuticals: Generic) experienced а -19.31% price change this week, while OASMY (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Reported Earning Dates

OASMY is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OASMY($13.7M) has a higher market cap than MVMDF($5.12M). MVMDF YTD gains are higher at: -33.206 vs. OASMY (-50.000). MVMDF has higher annual earnings (EBITDA): -3M vs. OASMY (-34.25M). OASMY has more cash in the bank: 23.6M vs. MVMDF (2.36M). MVMDF has higher revenues than OASMY: MVMDF (31K) vs OASMY (0).
MVMDFOASMYMVMDF / OASMY
Capitalization5.12M13.7M37%
EBITDA-3M-34.25M9%
Gain YTD-33.206-50.00066%
P/E RatioN/AN/A-
Revenue31K0-
Total Cash2.36M23.6M10%
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
MVMDF vs OASMY: Fundamental Ratings
MVMDF
OASMY
OUTLOOK RATING
1..100
2425
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
6485
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2830

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OASMY's Valuation (41) in the null industry is in the same range as MVMDF (53). This means that OASMY’s stock grew similarly to MVMDF’s over the last 12 months.

OASMY's Profit vs Risk Rating (100) in the null industry is in the same range as MVMDF (100). This means that OASMY’s stock grew similarly to MVMDF’s over the last 12 months.

OASMY's SMR Rating (95) in the null industry is in the same range as MVMDF (96). This means that OASMY’s stock grew similarly to MVMDF’s over the last 12 months.

MVMDF's Price Growth Rating (64) in the null industry is in the same range as OASMY (85). This means that MVMDF’s stock grew similarly to OASMY’s over the last 12 months.

MVMDF's P/E Growth Rating (100) in the null industry is in the same range as OASMY (100). This means that MVMDF’s stock grew similarly to OASMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MVMDFOASMY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
22%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
13%
Advances
ODDS (%)
Bullish Trend 6 days ago
82%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MVMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PSTV0.630.09
+15.81%
Plus Therapeutics
WAY36.080.56
+1.58%
Waystar Holding Corp
BA235.262.07
+0.89%
Boeing Company
GSBD11.13-0.11
-0.98%
Goldman Sachs BDC
RNGR12.58-0.18
-1.41%
Ranger Energy Services

MVMDF and

Correlation & Price change

A.I.dvisor tells us that MVMDF and MCUJF have been poorly correlated (+11% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MVMDF and MCUJF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MVMDF
1D Price
Change %
MVMDF100%
-22.01%
MCUJF - MVMDF
11%
Poorly correlated
N/A
OASMY - MVMDF
9%
Poorly correlated
N/A
OILFF - MVMDF
7%
Poorly correlated
+0.26%
MEDIF - MVMDF
0%
Poorly correlated
-7.67%
MKGAF - MVMDF
-1%
Poorly correlated
+1.94%
More